Clinical Trial Update: IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC [Phase 2]

View source ↗

Summary

Phase 2 trial results of IO102-IO103 in combination with pembrolizumab as first-line therapy for metastatic non-small cell lung cancer, head and neck squamous c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• IO102
• IO103
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: IO Biotech | Conditions: Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2026-04-08